There is a lack of sustained and sufficient funding, with high levels of competition for
funding and need for prioritisation.
Healthcare professionals struggle to run investigator-driven clinical trials since the entry into
force of the driven EU Clinical Trial Directive (2001/20/EC) in 2004.
Although the new EU Clinical Trial Regulation (536/2014/EU) may facilitate academic
research when it will be implemented (in 2016), however, it will not address all the existing
There is still poor access to new paediatric drugs in Europe, despite the EU
Paediatric Medicine Regulation (1901/2006/EC and 1902/2006/EC) – which nevertheless
changed the landscape of childhood cancer drug development in Europe.
There is insufficient integration between basic biology and clinical research, although
there have been several successful EU projects (including KidsCancerKinome, EET-pipeline,
ChildHope) funded within the 5th and 6th Framework Programmes.
There are considerable disparities in Europe in the implementation of research (clinical,
translational and basic) and in access to standard care, in particular for TYA.
Paediatric haematology-oncology is not recognised as a sub-specialty in most countries.
Parents, patients and survivors’ organisations lack tools and
platforms to better join forces with all stakeholders.
A certain level of fragmentation of research remains, in
spite of a long history of networking and major efforts
to build together a common infrastructure.
Paediatric haematology-oncology has grown and achieved
successes so far in relative isolation in comparison with the
adult oncology community.
The availability of high-throughput technologies that can quickly deal with large numbers of
samples will allow new breakthroughs in understanding paediatric tumour biology.
The development of effective innovative therapies (such as targeted agents and
immunotherapy) in adult cancers should be applicable to the treatment of paediatric
Paediatric haematology-oncology is now part of the EU agenda, as illustrated by ENCCA – a
FP7 network of excellence structuring paediatric cancer research in Europe – and
ExPO-r-Net, a DG SANTE project piloting the concept of European Reference Networks ERN)
within the scope of the EU Cross-Border Healthcare Directive (2011/24/EU).
A EUROPEAN CANCER PLAN FOR CHILDREN AND ADOLESCENTS
Credit Sociedade de Hemato-Oncologia Pediátrica